TheEdgeResearch
Home / Stocks / DRRX

DURECT Corporation (DRRX)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$1.91 ▼ -1.04%
Market Cap
$59.3M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.93
52-Wk Range
0.48-2.64
CEO
James E. Brown D.V.M.
Country
US
Currency
USD

DURECT Corporation operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Cupertino, CA, US. The stock last traded at $1.91, down 1.04% on the session, giving a market capitalisation of $59.3M. On trailing twelve-month figures it carries a trailing P/E of -9.41, a net margin of -846.0%. Its beta of 0.93 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-9.41
Price / Sales
77.23
Price / Book
15.06
EV / EBITDA
-8.64
Gross margin
90.1%
Operating margin
-903.9%
Net margin
-846.0%
Return on equity
Debt / equity
0.44
Current ratio
0.98
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
21
IPO date
2000-09-28
Headquarters
Cupertino, CA, US
About DURECT Corporation

DURECT Corporation is a biopharmaceutical enterprise dedicated to the research and development of innovative medicines, leveraging its epigenetic regulator and pharmaceutical platforms. The company provides the ALZET product range, which includes osmotic pumps and associated accessories vital for research studies conducted on mice, rats, and other laboratory animals. In its development pipeline, DURECT is advancing larsucosterol (DUR-928), an endogenous, orally administered small molecule. This compound, currently undergoing a Phase IIb clinical trial for alcohol-associated hepatitis, is designed to regulate lipid metabolism, stress and inflammatory pathways, and cellular survival and death. A Phase Ib clinical trial for patients with nonalcoholic steatohepatitis has also been successfully completed. Additionally, DURECT markets POSIMIR, a product aimed at managing post-surgical pain in adults by delivering bupivacaine for an extended period. The company also offers Methydur, a treatment for attention deficit hyperactivity disorder. Sales of the ALZET product line are managed by an in-house sales force across the United States and through an extensive network of distributors internationally, including Japan and Europe. DURECT Corporation engages in strategic collaborations and agreements with various partners, such as the Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Santen Pharmaceutical Co., Ltd. Established in 1998, DURECT Corporation maintains its headquarters in Cupertino, California.

Comparable companies

DURECT Corporation is most often compared with the following Healthcare names:

ACHLHTBXLFWDLIENQLIRPHMSHOTTCRRVLNSZYNE
More research on DRRX
DRRX technical analysis DRRX TheEdge Score Compare against peers
Open full interactive analysis & DCF →